To determine the impact of LPIN1 silencing on primary AML cells, three patient‐derived xenograft (PDX) AML samples including one with complex karyotype and TP53 mutation (AML‐661, AML‐372, and AML‐602; see Table S3 for genetic details) were transduced with shRNAs against LPIN1 or shLuc control. Here, TP53 is linked to acute myeloid leukemia.